Jonathan Anderman net worth and biography

Jonathan Anderman Biography and Net Worth

Insider of Compass Therapeutics

Jonathan Anderman, JD, joined Compass in August 2021. He serves as Senior Vice President, General Counsel and Corporate Secretary. He brings deep legal experience in the healthcare and life sciences industry, having served as in-house and outside counsel to biotechnology companies of various stages and sizes across multiple therapeutic areas. In these roles, Jon provided strategic guidance on the broad legal challenges relevant to developing and commercializing innovative products.

Immediately prior to joining Compass, Jon was Global Commercial Counsel at Biogen and, prior to that, Assistant General Counsel at Intarcia Therapeutics, where he advised on diverse areas ranging from corporate transactions to commercialization and compliance. Earlier in his career, Jon was a healthcare and life sciences attorney at the global law firm, Holland & Knight. At H&K, Jon represented clients throughout the healthcare sector on regulatory, transactional, and compliance matters.

Jon earned his JD from Boston University School of Law and his BA from the Pennsylvania State University.

What is Jonathan Anderman's net worth?: The estimated net worth of Jonathan Anderman is at least $116.34 thousand as of April 7th, 2025. Anderman owns 21,000 shares of Compass Therapeutics stock worth more than $116,340 as of December 5th. This net worth evaluation does not reflect any other investments that Anderman may own. Learn More about Jonathan Anderman's net worth.
How do I contact Jonathan Anderman?: The corporate mailing address for Anderman and other Compass Therapeutics executives is , , . Compass Therapeutics can also be reached via phone at 617-500-8099 and via email at [email protected]. Learn More on Jonathan Anderman's contact information.
Has Jonathan Anderman been buying or selling shares of Compass Therapeutics?: Jonathan Anderman has not been actively trading shares of Compass Therapeutics within the last three months. Most recently, on Monday, April 7th, Jonathan Anderman bought 20,000 shares of Compass Therapeutics stock. The stock was acquired at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the transaction, the insider now directly owns 21,000 shares of the company's stock, valued at $32,340. Learn More on Jonathan Anderman's trading history.
Who are Compass Therapeutics' active insiders?: Compass Therapeutics' insider roster includes Jonathan Anderman (Insider), Carl Gordon (Director), and Thomas Schuetz (CEO). Learn More on Compass Therapeutics' active insiders.
Are insiders buying or selling shares of Compass Therapeutics?: During the last twelve months, Compass Therapeutics insiders bought shares 2 times. They purchased a total of 30,000 shares worth more than $51,900.00. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 3,571,428 shares worth more than $5,678,570.52. The most recent insider tranaction occured on May, 27th when CEO Thomas J Schuetz bought 10,000 shares worth more than $21,100.00. Insiders at Compass Therapeutics own 29.8% of the company. Learn More about insider trades at Compass Therapeutics.
Information on this page was last updated on 5/27/2025.

Jonathan Anderman Insider Trading History at Compass Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/7/2025	Buy	20,000	$1.54	$30,800.00	21,000

Jonathan Anderman Buying and Selling Activity at Compass Therapeutics

Compass Therapeutics Company Overview

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $5.54

$5.25

$5.61

50 Day Range

MA: $4.37

$3.36

$5.90

2 Week Range

Now: $5.54

$1.33

$5.86

Volume

1,473,044 shs

Average Volume

2,123,114 shs

Market Capitalization

$985.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44